New Wave Ventures

Regenerys develops and sells regenerative medicine products in the streams requiring bioprocessing and biostorage. It offers Myskin, a product for the autologous treatment of serious burns and difficult to heal wounds using cultured allegoneic cells from the patient’s own skin; and Cryoskin, a medicine for the treatment of burns using autologous cells. Regenerys also provides Adiposet, a service to facilitate better cosmetic outcomes in breast cancer surgery and other cosmetic procedures by enabling the storage and return of adipose tissue for lipomodellin. In addition, it offers third party bio-processing and bio-storage services through its laboratories. Regenerys serves NHS and private healthcare providers in the United Kingdom and other parts of Europe. It began operation in 2011, with its headquarters in Cambridge in the United Kingdom.

Xerion Healthcare develop nanoparticles that are used to improve treatment of cancer. The nanoparticles are injected into tumours just prior to standard radiotherapy and act to enhance the effectiveness of the treatment, amplifying the dose of free radicals generated by the X-rays. The nanoparticles are based on titanium dioxide, a common, non-toxic, semiconductor material. Xerion Healthcare are currently developing the treatment for head and neck and pancreatic tumours.

Spectromics develops a diagnostic system that helps to guide antibiotic treatment. It provides a point-of-prescription test for bacterial infections that guides the treatment of antibiotics. Spectromics began operation in 2014. Its headquarters is in Manchester in the United Kingdom.

Surface Generation is a privately-owned high technology and manufacturing company headquartered in the UK and with facilities in North America and Asia. Its patented Production to Functional Specification (PtFS) technology enables manufacturers in the aerospace, automotive and consumer electronics sectors to work with composite materials, saving costs, energy and producing significantly lighter weight products.

Atto takes the lead with a clear mission, to shape a more predictable future for lenders. Using real-time bank transaction data, Atto delivers a suite of predictive models to empower risk management. Atto offers a range of insights that gives risk managers a detailed view of customer spending, saving, and earning. This added level of understanding enhances credit risk assessment and promotes a more compliant lending environment. Providing accurate foresight lies at the heart of Atto's values. By leveraging current financial information, consumers are more likely to receive equitable treatment, whilst businesses gain the tools to make more informed and appropriate lending decisions. With innovation in data science at its core, Atto paves the way for a future where complex decisions can be made in real-time with impossibly recent data.

Nanna Therapeutics is a drug discovery company addressing age-related diseases for which others are failing to provide effective treatments. These include mitochondrial, neurodegenerative, cardiovascular or metabolic, joint or tissue disease as well as cancer. Nanna Therapeutics are targeting fundamental cellular processes to create drugs to treat age-related diseases and improve longevity. Such drugs include those to combat debilitating neurodegenerative, inflammatory, cardiovascular and metabolic diseases as well as many cancers. With a strong focus on mitochondria, the energy source in every cell, we can target the fundamental causes of many age-related diseases. Through this approach we can also address debilitating, life-limiting mitochondrial diseases for which there are currently few effective therapies. Nanna Therapeutics has developed a tightly integrated set of proprietary technologies that radically disrupt current methods of creating new medicines. This Totally Integrated Medicines Engine (TIME) has been devised to answer the needs of drug discovery and development scientists utilising the best in 21st century technologies of microfluidics, nanofabrication and artificial intelligence.

Endomag is a medical technology company devoted to improving the global standard of cancer care. The company's Sentimag probe, Magseed marker, and Magtrac node marker are already in use by many of the world’s leading physicians and cancer centers. Endomag's goal is to help women with breast cancer avoid surgery when it isn’t needed, and experience better outcomes when it is. As of 2019, the company has already helped 70,000+ women around the world access more precise and less invasive breast cancer care. Founded in 2007 as a spin-out from the University of Houston and the University College London (UCL), Endomag continues to develop its unique clinical platform from its headquarters in Cambridge, United Kingdom. The company sells its products through a network of distributors in Europe, the Middle East, Africa, and Australasia.

Atto takes the lead with a clear mission, to shape a more predictable future for lenders. Using real-time bank transaction data, Atto delivers a suite of predictive models to empower risk management. Atto offers a range of insights that gives risk managers a detailed view of customer spending, saving, and earning. This added level of understanding enhances credit risk assessment and promotes a more compliant lending environment. Providing accurate foresight lies at the heart of Atto's values. By leveraging current financial information, consumers are more likely to receive equitable treatment, whilst businesses gain the tools to make more informed and appropriate lending decisions. With innovation in data science at its core, Atto paves the way for a future where complex decisions can be made in real-time with impossibly recent data.

SPARKL designs and develops the SPARKL Sequencing Engine, which lets you manage the behaviour of all your distributed machines, systems and applications. It uses our simple, declarative Clear Box configuration to make them work together intelligently, generating a tamper-proof audit trail for regulatory compliance and system performance. SPARKL is based in London and works with partners including Cisco and Intel to market the product to users and customers worldwide.

Endomag is a medical technology company devoted to improving the global standard of cancer care. The company's Sentimag probe, Magseed marker, and Magtrac node marker are already in use by many of the world’s leading physicians and cancer centers. Endomag's goal is to help women with breast cancer avoid surgery when it isn’t needed, and experience better outcomes when it is. As of 2019, the company has already helped 70,000+ women around the world access more precise and less invasive breast cancer care. Founded in 2007 as a spin-out from the University of Houston and the University College London (UCL), Endomag continues to develop its unique clinical platform from its headquarters in Cambridge, United Kingdom. The company sells its products through a network of distributors in Europe, the Middle East, Africa, and Australasia.

Atto takes the lead with a clear mission, to shape a more predictable future for lenders. Using real-time bank transaction data, Atto delivers a suite of predictive models to empower risk management. Atto offers a range of insights that gives risk managers a detailed view of customer spending, saving, and earning. This added level of understanding enhances credit risk assessment and promotes a more compliant lending environment. Providing accurate foresight lies at the heart of Atto's values. By leveraging current financial information, consumers are more likely to receive equitable treatment, whilst businesses gain the tools to make more informed and appropriate lending decisions. With innovation in data science at its core, Atto paves the way for a future where complex decisions can be made in real-time with impossibly recent data.

Tapit is a pioneer within the contactless communications sector (mobile 3.0). Since 2011 Tapit has worked with global brands including Google, Microsoft, Samsung & Visa to deploy, manage and analyse their contactless infrastructure including NFC tags, Beacons and QR codes. Leveraging Tapit and the power of contactless communications provides global companies with a fast, simple and secure way to engage with consumers via their smartphone directly from physical environments such as outdoor media and retail.

Atto takes the lead with a clear mission, to shape a more predictable future for lenders. Using real-time bank transaction data, Atto delivers a suite of predictive models to empower risk management. Atto offers a range of insights that gives risk managers a detailed view of customer spending, saving, and earning. This added level of understanding enhances credit risk assessment and promotes a more compliant lending environment. Providing accurate foresight lies at the heart of Atto's values. By leveraging current financial information, consumers are more likely to receive equitable treatment, whilst businesses gain the tools to make more informed and appropriate lending decisions. With innovation in data science at its core, Atto paves the way for a future where complex decisions can be made in real-time with impossibly recent data.

Surrey NanoSystems manufactures nanoscale materials for use in engineering and product applications. It offers Vantablack, a super-black coating that is applied to surfaces using vacuum-deposition technology, as well as for spraying and post-processing. Surrey NanoSystem’s Vantablack is used in various applications, such as stray light suppression, architectural lighting, aesthetic applications, calibration sources, sensors, telescopes, architecture, IR imaging systems, spectroscopy, automotive, cinematography optics, satellite calibration sources, camera lenses, and other applications. CEVP that began operation in 2006 became Surrey NanoSystems in December 2006, with its headquarters in Newhaven in the United Kingdom.

Enhanced Telecommunications Ltd, dba Netmania Solutions, specialist device management practitioners with experience of standards based solutions, has been involved in TR-069 delivery and deployments since 2001, enabling operators to improve the customer journey, reduce churn and improve profitability.

Endomag is a medical technology company devoted to improving the global standard of cancer care. The company's Sentimag probe, Magseed marker, and Magtrac node marker are already in use by many of the world’s leading physicians and cancer centers. Endomag's goal is to help women with breast cancer avoid surgery when it isn’t needed, and experience better outcomes when it is. As of 2019, the company has already helped 70,000+ women around the world access more precise and less invasive breast cancer care. Founded in 2007 as a spin-out from the University of Houston and the University College London (UCL), Endomag continues to develop its unique clinical platform from its headquarters in Cambridge, United Kingdom. The company sells its products through a network of distributors in Europe, the Middle East, Africa, and Australasia.

Orthogem develops and manufactures synthetic bone grafts. Its patented Tripore technology platform has enabled the creation of a pipeline of SBG's formulated for a variety of clinical applications, ranging from spinal to oral cranial facial surgery. Orthogem's products include TriPore Granules, TriPore MPA, and TriPore Blocks. Wei Lo founded it in 2001, with its headquarters in Nottingham in the United Kingdom.

Aeristech as an engineering R&D consultancy firm to develop Hybrid Turbo Technology.